ReviewReviews in endocrine & metabolic disorders2007
Genetic susceptibility to breast cancer.
Review in Reviews in endocrine & metabolic disorders, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 102 citations in OpenAlex.
- Breastfeeding and breast cancer risk by receptor status--a systematic review and meta-analysis.Annals of oncology : official journal of the European Society for Medical Oncology · 2015Pooled it
- Breast Self-Examination Practice Among Female University Students in Ethiopia: A Systematic Review and Meta-Analysis.Cancer control : journal of the Moffitt Cancer CenterPooled it
- Functional characterization of BRCA1 variants of unknown significance using homologous recombination repair assays.Breast cancer research : BCR · 2025Article
- An Investigation of theMedical sciences (Basel, Switzerland) · 2025Article
- Genetic insights into BRCA1/2 associated breast cancer in Türkiye: focus on early-onset and aggressive subtypes.Discover oncology · 2025Article
- Dietary-Based Diabetes Risk Score and breast cancer: a prospective evaluation in the SUN project.Journal of physiology and biochemistry · 2025Article
- Comprehensive genomic profiling of breast cancers characterizes germline-somatic mutation interactions mediating therapeutic vulnerabilities.Cell discovery · 2023Article
- Circulating tumor biomarkers in early-stage breast cancer: characteristics, detection, and clinical developments.Frontiers in oncology · 2023Review
- Breast cancer in the era of precision medicine.Molecular biology reports · 2022Review
- Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.Journal of cellular and molecular medicine · 2022Review
- Germline mutations in Chinese ovarian cancer with or without breast cancer.Molecular genetics & genomic medicine · 2022Article
- Global, regional, national burden of breast cancer in 185 countries: evidence from GLOBOCAN 2018.Breast cancer research and treatment · 2021Article
- The relationship between BRCA-associated breast cancer and age factors: an analysis of the Japanese HBOC consortium database.Journal of human genetics · 2021Article
- Association of the study between LncRNA-H19 gene polymorphisms with the risk of breast cancer.Journal of clinical laboratory analysis · 2019Article
- Association of Single-Nucleotide Polymorphisms in Monoubiquitinated FANCD2-DNA Damage Repair Pathway Genes With Breast Cancer in the Chinese Population.Technology in cancer research & treatment · 2018Article
- Analysis of BRCA1/2 mutation spectrum and prevalence in unselected Chinese breast cancer patients by next-generation sequencing.Journal of cancer research and clinical oncology · 2017Article
- Next-Generation Sequencing Reveals a Nonsense Mutation (p.Arg364Ter) inBreast care (Basel, Switzerland) · 2017Article
- Germline BRCA testing is moving from cancer risk assessment to a predictive biomarker for targeting cancer therapeutics.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2016Article
- Genetic Polymorphisms in Long Noncoding RNA H19 Are Associated With Susceptibility to Breast Cancer in Chinese Population.Medicine · 2016Observational
- MicroRNA-101 inhibits cell progression and increases paclitaxel sensitivity by suppressing MCL-1 expression in human triple-negative breast cancer.Oncotarget · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Deleterious mutations in two breast and ovarian cancer susceptibility genes, BRCA1 and BRCA2 have been identified in breast and ovarian cancer families. Women with a BRCA1 or BRCA2 mutation are candidates for additional risk reduction measures such as intensive screening, prophylactic surgery or chemoprevention. Additional susceptibility genes have been identified, including PTEN, ATM, TP53, CHEK2, CASP8, PBRL and BRIP1. Yet, many women with a personal or family history suggestive of a hereditary susceptibility to breast cancer undergo genetic testing and no significant genetic alteration is found. Thus, there are other susceptibility genes that have not been identified, and it is likely that the remaining familial contribution to breast cancer will be explained by the presence of multiple low penetrance alleles that coexist to confer high penetrance risks (a polygenic model). The American Cancer Society has identified cancer prevention as a key component of cancer management and there is interest in developing individualized cancer prevention focused on identifying high risk individuals who are most likely to benefit from more aggressive risk reduction measures. Breast cancer risk assessment and genetic counseling are currently provided by genetic counselors, oncology nurse specialist, geneticists, medical and surgical oncologists, gynecologists and other health care professionals, often working within a multidisciplinary clinical setting. Current methods for risk assessment and predictive genetic testing have limitations and improvements in molecular testing and risk assessment tools is necessary to maximize individual breast cancer risk assessment and to fulfill the promise of cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.